Akut Miyeloid Lösemi Hastalarında İdame Tedavilerin Sağkalım Üzerine Etkisi ve İdame Tedavilerin Karşılaştırılması

Abstract

Although maintenance therapies are given to acute myeloid leukaemia (AML) patients to improve survival, data on this subject are limited in the literature. The aim of our study was to retrospectively analyse the effect of maintenance chemotherapies on overall survival (OS) and disease-free survival (DFS) in AML patients who were followed up in our clinic between 2003 and 2023. In patients who went into remission but could not undergo AHSCT, the median overall survival time, 1st and 3rd year overall survival rates, 1st year disease-free survival rate, and median disease-free survival time of the group receiving maintenance therapy were found to be higher than the group not receiving maintenance therapy. It was determined that maintenance protocols such as Venetoclax-Azacitidine, Azacitidine and low dose ARA-C did not make a significant difference in terms of overall or disease-free survival time and overall or overall survival rates compared to patients who did not receive any maintenance therapy. In patients who went into remission and underwent AHSCT, no statistically significant difference was found in overall or disease-free survival compared to the patient group who received maintenance therapy and the patient group who did not receive any maintenance therapy. The mean overall or disease-free survival time and 1- and 3-year overall or disease-free survival rates were significantly higher in patients treated with the TAD protocol compared to other maintenance protocols. When analysed in terms of side effect profile, no significant difference was found between maintenance therapy protocols. These results suggest that maintenance therapy may increase overall survival in AML patients who could not undergo AHSCT, and especially the TAD protocol stands out in terms of both survival advantage and side effect profile. We recommend giving maintenance therapy with the TAD protocol to patients in remission who cannot undergo AHSCT.